553P - Age dependent increase in median and long-term survival in 29 628 metastatic colorectal cancer (mCRC) Scandinavian patients during the past two deca...
|Date||01 October 2012|
|Event||ESMO Congress 2012|
|Session||Poster presentation III|
|Topics|| Cancer Aetiology, Epidemiology, Prevention
C. Qvortrup1, M. Cvancarova2, B. Glimelius3, P. Pfeiffer1, H. Sorbye4
In mCRC studies, median survival has increased from 6-8 months to above 20 months during the last decades. Uncertainty exists whether this improvement in survival is also seen in a general mCRC population or in selected subgroups.Methods
Survival data from patients with synchronous mCRC were collected from Norwegian (1980-2008), Swedish (1996-2008, Uppsala/ Orebro and Stockholm) and Danish (2001-2009) cancer registries. Survival was modeled using Kaplan-Meier method and the differences assessed with log-rank test.Results
A total of 18 114 Norwegian, 6477 Danish and 5037 Swedish patients were identified. The percentage of stage IV, Norwegian CRC patients at initial diagnosis was 22% and unchanged during the study period. From 1980-85 to 2006-08, median survival increased from 5 months (95% CI 4.7-5.3) to 10 months (95% CI 9.1-10.9) for Norwegian patients. Three-year survival increased from 7% to 21% (p < 0.001) and five-year survival from 4% to 9% (p < 0.001) in the same period. Younger patients had significantly higher median and long-term survival, and the increase in survival in recent years was much higher for younger patients. For age groups <60 years, median survival has doubled from 8 to 16 months and the most recent survival estimates were 14% (5-year) and 28% (3-year). A similar improvement in median survival and 3-year survival was seen in Sweden (8 to 11 months and 11% to 21% (p < 0.001) from 1996-2001 to 2006-2008 and in Denmark (7 to 10 months and 12 to 18% (p < 0.001) from 2001-2005 to 2006-09). No increase in survival was observed in patients above 80 years.Conclusions
The study shows a marked improvement in median and long-term survival from 1980 to 2008 in an unselected population of patients with synchronous mCRC. We believe this survival benefit mainly reflects increased use of more effective systemic therapy. Median and long-term survival were highly dependent on age at diagnosis, as the recent improvement in survival was most pronounced for younger patients.Disclosure
P. Pfeiffer: Research funding: Merck and Roche Advisory board: Merck, Roche and Amgen.
H. Sorbye: Research funding Merck, Roche and Amgen.
All other authors have declared no conflicts of interest.